Abstract 377P
Background
Human papillomavirus (HPV) associated oropharyngeal squamous cell cancers (OPSCC) are known to have better treatment response and outcome compared with HPV -negative ones. Testing for p16 expression is used as a surrogate for HPV testing. While p16- positive tumours comprise of majority of OPSCC in Western population, p16 -positive tumours in Asian population have remained low.
Methods
Data of Indian patients treated at a single institute between 2016 -2023 was ambispectively analyzed for rate of p16 positivity and clinical outcomes. Staining of ≥70% was considered positive for p16. Data entry and analysis was done using IBM SPSS Statistics v21.0.
Results
Between February 2016 – June 2023, 114 patients were treated, of which 106 had SCC. Majority subsites were tonsil (50, 47.2%), base of tongue (30, 28.3%), and soft palate (15, 14.2%). Testing for p16 was done in 66 patients (62%), of which 19 were p16-positive. Smoking history was noted in 36 patients (34%). Treatment modalities were CTRT for 74 patients (69.8%) and RT alone for 32 (30.2%). IMRT was utilized for majority patients (97, 91.5%). Chemotherapeutic agents were cisplatin for 61 (82.4%, 6 (9.8%) shifted to carboplatin) [3 weekly-9, weekly-52], carboplatin 11 (15%) and cetuximab 2 (3%). Treatment was completed by 101 patients (95.3%) [2 discontinued treatment, 3 died before treatment completion due to non-oncologic causes]. At 3 months, response assessment was done for 94 patients, of which 74 (78.7%) had complete response [14/15 (93.3%) p16-positive, 31/41 (75.6%) p16-negative]; 7 patients (7.4%) had incomplete response while 13 (13.8%) progressed. At median follow-up of 23 months (IQR 11–42); 90 patients were alive, 72 (71.3%) had disease under control. Relapse was seen in 9 patients (p16-positive – 0, p16-negative – 4, untested – 5). Median progression free survival was 17 months (IQR 5-37 months).
Conclusions
While p16 positivity amongst Indian OPSCC patients remains lower than Western counterparts, p16 -positive OPSCC have shown favorable response rates in Indian patients. Association of p16 positivity with improved response rates and fewer relapses in the Indian population warrants investigation in a larger randomized trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amrita Cancer Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract